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Over the past three decades, the outcome of Ewing sarcoma family tumor (ESFT) patients who are nonmetastatic at presentation
has improved considerably. The prognosis of patients with metastatic disease at the time of diagnosis and recurrence after therapy
remains dismal. Drug-resistant disease at diagnosis or at relapse remains a major cause of mortality among patients diagnosed
with ESFT. In order to improve the outcome for patients with potential relapse, there is an urgent need to ﬁnd reliable markers
that either predict tumor behaviour at diagnosis or identify therapeutic molecular targets at the time of recurrence. An improved
understanding of the cell of origin and the molecular pathways that regulate tumorigenicity in ESFT should aid us in the search for
novel therapies for ESFT. The purpose of this paper is thus to outline current concepts of sarcomagenesis in ESFT and to discuss
ESFT patterns of diﬀerentiation and molecular markers that might aﬀect prognosis or direct future therapeutic development.
1.Introduction
Since James Ewing in 1921 ﬁrst described a diﬀuse heman-
gioendothelioma of bone [1] ,s e v e r a ls t u d i e sh a v ea t t e m p t e d
to elucidate the histogenesis of Ewing’s sarcoma (ES) [2, 3].
Based on histology, electron microscopy, and immunostains,
it was postulated that ES represents a primitive mesenchymal
neoplasm with the potential for multidirectional diﬀerenti-
ation [2]. Neural and neuroectodermal diﬀerentiation was
demonstratedincelllines[4,5]andtissuesections[6,7],and
tumors with the histology of Ewing sarcomas were described
in soft tissue [8–10]. Lesions with atypical features also
appeared [11]. Askin et al. [12] described a distinctive neo-
plasm in the chest wall that we now recognize as belonging
to this group of cancers. Originally, neuroectodermal tumors
of bone [13] and soft tissue [8] were described as a separate
entities, but some overlap became apparent [14]. The term
“primitive neuroectodermal tumor” (PNET) was given to
these latter lesions, and the sobriquet “peripheral PNET”
(pPNET) was later applied to separate them from unrelated
lesions of the central nervous system [15]. With the ﬁnding
ofspeciﬁctranslocationst(11;22)andt(21;22)andaccompa-
nying genetic fusions, it became generally accepted that ES of
bone and soft tissue, pPNET of bone and soft tissue, Askin’s
t u m o r ,a n dE Sw i t hn e u r a ld i ﬀerentiation represent a single
tumor entity with common antigenic proﬁles, cytogenetic
aberrations, and protooncogene expression. This common
entity, which has been designated the Ewing sarcoma family
of tumors (ESFT), possesses a limited capacity for several
diﬀerent degrees of diﬀerentiation [16–18].
The cell of origin for ESFTs has been hotly debated ever
since their discovery [16, 19, 20]. Candidates have included
neuroectodermal and mesenchymal cells of hematopoietic
and nonhematopoietic origin. Human marrow mesenchy-
mal stem cells (MSCs) currently appear to be a strong
candidate as the cell of origin of ESFT. MSCs are permissive
for the characteristic EWS-FLI1 fusion and can initiate
reprogramming toward ES cancer stem cells [20, 21].
The overall prognosis of ESFT has improved with
the improved use of chemotherapy for localized tumors.2 Sarcoma
Figure 1: Classical Ewing’s sarcoma, microscopic image of typical
histomorphology. The lesion comprises patternless sheets of small
bluecellswithround,regularnuclei,evennuclearmargins,minimal
cytoplasm, and indistinct boundaries.
However, metastatic and recurrent disease still has a dis-
mal prognosis. A number of pathological and molecular
characteristics have been linked to the clinical outcome
of ESFT. In this paper, we will outline the pathological
features of ESFT, review the current concepts about their
sarcomagenesis, discuss their capacity for multipotential
diﬀerentiation, and focus on the controversies and impact of
neural diﬀerentiation and other pathobiological parameters
in patient outcome.
2.Morphology
Before cytogenetics established that ES and pPNET share
the balanced translocation t(11;22) (q24;q12) in over 90%
of cases [22], ES and pPNET were regarded as totally
separate entities distinguished by their morphologic and
ultrastructural characteristics. ES occurred primarily in
bone and pPNET in soft tissue. However, these boundaries
crumbled with reports of discrepant features, such as an
extraskeletalneoplasmresemblingES[9],aneuroectodermal
tumor of bone [13], and ES with neural features [14].
Thanks to cytogenetic and molecular studies, it is now
accepted that ES and pPNET comprise opposite poles of
a histological continuum of a single group of neoplasms.
In between lie lesions with varying degrees of atypical
features (atypical ES) and diﬀerentiation. With the use of
genetic tools, evidence emerged that morphological and
immunohistochemical spectrum of ESFT may be broader
than has traditionally been accepted [23], and additional
histological patterns of ESFT have now been described [23,
24]. The histology of ESFT can be described as “classical”,
“atypical”,or“variant”.Thefollowingsectionwilldetailthese
histological features.
2.1.ClassicalEwingSarcomaHistology. Microscopically,clas-
sical (typical) ES is the prototypic undiﬀerentiated small
round cell tumor, composed of sheets of monotonous round
or oval cells with primitive-appearing nuclei and moder-
ate amount of clear to amphophilic cytoplasm (Figure 1).
The nuclear characteristics of the prototypic ES are those of
a primitive uncommitted cell, that is an oval conﬁguration
with smooth contours, single inconspicuous nucleoli, and
ﬁnely dispersed chromatin. The nuclei are generally centrally
located and surrounded by a thin rim of clear to vacuo-
lated cytoplasm. The lesions are highly cellular with little
intervening intercellular space. Paradoxically, typical cases
contain few mitoses. Cytologically, these tumors comprise
a mixture of lightly staining “primary” cells and darkly
staining “secondary” cells. Some feel that the “secondary”
cells are eﬀete versions of the “primary cells” that result from
degenerative changes that lead to nuclear hyperchromasia or
basophilia, but some ultrastructural studies show no signs of
degenerative changes [25] .S i x t yt os e v e n t y - ﬁ v ep e rc e n to f
ESFTs [23, 24] are reported to have this classical histology
(Table 1).
2.2. Variant Histologies
2.2.1. Atypical ES (or Large Cell ES). The cells of atypical
ES are larger and more pleomorphic. They contain pleo-
morphic nuclei with indented, irregular nuclear membranes,
conspicuous nucleoli, and increased amounts of cytoplasm
that is often more eosinophilic than clear. The cells may con-
tain abundant intracytoplasmic glycogen that gives them a
clear appearance. A spindle-like conﬁguration with fusiform
nuclei can aﬀect more than 50% of the tumor ﬁeld. Atypical
variants with epithelioid or clear cells [24] and a synovial-
like pattern have been described [23]. Coincident with the
appearance of atypical features, increased mitotic activity
appears. Although frank neural diﬀerentiation by deﬁnition
should be lacking, subtle signs may appear by electron
microscopy or single immunostains.
2.2.2. pPNET. One of the best descriptions of pPNET was
written by Jaﬀe et al. [13], who described neuroectodermal
tumor of bone with prominent Homer Wright rosettes
(previouslycalled“malignantneuroepithelioma”or“periph-
eral neuroepithelioma”). They proposed this entity to be a
distinct neoplasm, although the Intergroup Ewing Sarcoma
Study had included rosette-forming lesions as a form of
ES [26]. Jaﬀe et al. noted that no attempt had been made
in prior publications to distinguish Homer Wright rosettes
from perivascular or apoptotic pseudorosettes, and they
postulated that Homer Wright rosettes are a marker for
pPNET. This observation was later conﬁrmed by Llombart-
Bosch and Schmidt [7, 27]. As per the original description
of neuroblastoma by James Homer Wright, these rosettes
should consist of a closely apposed circle of cells with a
peripheral wreath of nuclei and a central core of neuropil
(Figure 2). The number of rosettes found in pPNETs varies
fromisolatedtonumerous.Ifisolated,theygenerallycontrast
with the background of monotonous ﬁelds of small round
bluecells,butattimesthehistologycanbesubtle.Lesionsare
termed pPNET independent of the degree of diﬀerentiation
and the number of rosettes. Jaﬀe presciently proposed that
ES may be the most undiﬀerentiated form of pPNET.
Subsequently, several retrospective studies indicated that by
immunohistochemistry features of neural diﬀerentiation canSarcoma 3
Table 1: Morphological patterns described in two recent reviews of ESFT [23, 24].
Number of cases Classical pPNET Atypical Spindle Sclerosing Adamantinoid Reference
66 46 9 3 3 2 3 [23]
415 280 53 82 nr nr nr [24]
Nr: not reported.
Figure2:PeripheralprimitiveneuroectodermaltumorwithHomer
Wrightrosettes.Therosettescontainacircularwreathofovalnuclei
that surround a pale eosinophilic, ﬁbrillary core.
also be revealed in ES, using antibodies against proteins such
as neuron-speciﬁc enolase, Leu 7 (later termed CD57), and
S100 [7, 28, 29]. In 1991 Schmidt et al. [27] proposed that
pPNET could be deﬁned as tumors having Homer-Wright
rosettes or expressing two diﬀerent neural immunomarkers.
Their retrospective study, which covered several decades
of treatment, indicated that pPNETs had a worse clinical
outcome than other forms of ESFT. Using Schmidt’s criteria,
the reported incidence of pPNET varies from 12% to 23%,
compared to other ESFTs (Table 2).
2.2.3. Adamantinoma-Like Pattern. This is a recently
described variant of ESFT described by Bridge et al. as an
example of “phenotypic drift” [30]. This pattern comprises
well-formed nests of moderately hyperchromatic cells
with striking peripheral palisading and a prominent host
desmoplastic response. Adamantinoma-like ESFTs are
positive for CD99, FLI1, pan-cytokeratin, and in distinction
fromotherformsofESFT,highmolecularweightcytokeratin
[23]. Note that cytogenetic features characteristic of ESFT
distinguish these lesions from true adamantinoma of bone
[30, 31].
2.2.4. Spindle Cell Sarcoma-Like Pattern. This is another
recently described pattern of ESFT, composed of intersecting
fascicles of spindle cells. It should however be noted that
brief mention of a similar lesion appeared in 1983 in the
description of “peripheral neuroepithelioma” in the ﬁrst
edition of Enzinger and Weiss’s classic textbook [32]. Rare
cases were also described in 1992 by Cavazzana et al. [33],
although genetic conﬁrmation was lacking at that time.
There are well-developed, branching intratumoral blood
vessels, reminiscent of hemangiopericytoma-like spindle cell
sarcomas such as synovial sarcoma. CD99 and FLI1 are
positive in all cases, and pan-cytokeratin is positive in two-
thirds. Conﬁrmatory genetic testing is required for this
diagnosis (see below).
2.2.5. Sclerosing. This new pattern is described as composed
of abundant hyalinised matrix. Two cases described by
[23] were felt to be reminiscent of sclerosing epithelioid
ﬁbrosarcoma or sclerosing rhabdomyosarcoma. The neo-
plasticcellsgenerallyresemblethecellsoftypicalESFT.CD99
and FLI1 were positive in all cases, pan-cytokeratin was
positive in 2 cases, and all were negative for high molecular
weight cytokeratin. This lesion must be distinguished from
desmoplastic small round cell tumor (DSRCT), which has a
diﬀerent cytogenetic aberration. However, rare tumors may
resemble DSRCT histologically and immunophenotypically
but contain cytogenetic features typical of ESFT [34].
2.2.6. Vascular-Like. Similar to Ewing’s original report of
“hemangioendotheliomaofbone”,theobservationthatsome
ESFTsresemblevascularlesionspersists.InLlombart-Bosch’s
series [24], there were 9 such cases (2%). ESFTs with this
pattern contain pseudoendothelial elements that produce
angiomatoid spaces lined by elongate tumor cells surround-
ing lacunae ﬁlled with erythrocytes and plasma. Unlike true
vessels, the cells lining the surface of the spaces lack basal
lamina and are in continuity with the surrounding typical
ES.Ofnote,structuresresemblingWeibel-Paladebodieshave
been described in some ultrastructural descriptions [35],
although genetic conﬁrmation was lacking in these early
reports.
2.3. Current Morphological Controversies. Two large recent
retrospective series of genetically conﬁrmed ESFT cases [23,
24] outline the heterogeneity of histological patterns in
these lesions (Table 1). It is unclear in these reports whether
the patterns were homogeneous or mixed in individual
tumors, and current limited pretreatment biopsies preclude
extensive histological assessment. In one of the series [24],
all the unusual histological subtypes were grouped under the
rubric of “atypical variant”. Patterns described as synovial-
sarcoma-like, sclerosing, and adamantinomatous were not
considered independent entities. Noteworthy is that unlike
Llombart-Bosch et al., the Folpe series did not report any
hemangioendotheliomatous cases, further emphasizing their
rarity as a subtype. Questions remain as to whether or
not unusual patterns may be seen in combination with the
classical pattern and whether the morphological phenotype
of recurrent tumors can be modiﬁed by chemotherapy.4 Sarcoma
Table 2: Immunohistochemical expression of ESFT markers.
Reference CD99 FLI1 CK (AE1/3) HMWCK desmin CD117 CAV1 CD57 (HNK1)
Folpe et al. [23] 100% 94% 32% 5% 2% 24% ND ND
Llombart-Bosch [24] 99% 89% ND ND ND ND 96% 53%
ND: not done; CK: cytokeratin; HMWCK: high molecular weight cytokeratin; CAV: caveolin 1; HNK1: human natural killer antigen 1.
Figure 3: Atypical Ewing sarcoma, postchemotherapy and recur-
rence. This recurrent ESFT displays epithelioid features, such as
increased eosinophilic cytoplasm and cohesive nests.
In our experience, we have seen one case of classical
ESFT histology that recurred with an atypical epithelioid
histological pattern (Figure 3). Others have described lesions
with ganglioneuroma-like features, both before [36]a n d
after [37] chemotherapy.
3. Immunohistochemistry
Traditionally, the diagnosis of ESFT has been made by exclu-
sion, but this situation considerably improved over the last
20 years with the introduction of new immunohistochemical
markers. These markers include CD99 [38], FLI1 [39], and
caveolin1 (CAV1) [24], which are commonly expressed in
ESFTs and diﬀerentiate them from other small round cell
tumors (Table 2). In addition, markers of neural, epithelial,
and mesenchymal diﬀerentiation have been described in var-
ious subsets of ESFT. In the following section, we will brieﬂy
describe the immunohistochemical markers associated with
ESFT.
3.1. CD99. CD99 is a membrane associated protein that
is closely related to the murine THY-1 antigens, major
cell surface glycoproteins of murine brain, and thymus
cells [40]. It is a 32 KDa membrane glycoprotein that is
highly expressed in most cases of ESFT [41]. This protein
is encoded by a pseudoautosomal gene found in both
X and Y chromosomes. CD99 is also known as MIC2
and is recognized by monoclonal antibodies 12E7, HBA71,
O13, and HO36-1.1. It has a key role in several biological
processes,including:celladhesion,migration,andapoptosis;
diﬀerentiation of T thymocytes; diapedesis of lymphocytes
to inﬂamed vascular endothelium; maintenance of cellular
morphology; and regulation of intracellular membrane
protein traﬃcking [42, 43]. Modulation of CD99 expression
signiﬁcantly modiﬁes cell growth in anchorage-independent
conditions, and it aﬀects cell migration, tumorigenesis, and
metastatic activity in other models.
In ESFT, CD99 appears to prevent terminal neural
diﬀerentiation [44] .T h i sp r o c e s si sd e p e n d e n to nc h a n g e s
in mitogen-activated protein kinase pathway signalling.
[44]. CD99 contributes to cell proliferation, migration, and
metastasisofESFTcells[44].Questionsremainastowhether
CD99 is a downstream target of EWS/FLI1.
3.2. FLI1. As will be described below in more detail, the
reciprocal translocation t(11;22) results in juxtaposition of
the amino terminal domain of EWS to the carboxyl terminus
of FLI1 [45]. FLI1 is normally expressed in endothelial
cells and hematopoietic cells, including T lymphocytes. It
is a member of the ETS (erythroblastosis virus-associated
transforming sequences) family of DNA-binding transcrip-
tion factors, and it is involved in cellular proliferation and
tumorigenesis[46].Folpeetal.[39]showedthatapolyclonal
antibody to the carboxyl terminus of FLI1 protein was a
relatively sensitive (71%) and highly speciﬁc (92%) marker
of ESFT.
These results and those of Nilsson et al. [47] indicate that
FLI1 antibodies may play a valuable role in the immunohis-
tochemical diagnosis of small blue round cell tumors. The
combination of CD99 and FLI1 immunostaining appears
to improve the speciﬁcity of these markers for diagnosis of
EWS/FLI1 fusion-positive ESFT [48].
3.3. Caveolin. Caveolae are plasma membrane invaginations
that regulate several intracellular signaling pathways. The
deﬁning components of caveolae are from 21 to 24kDa
molecules termed caveolins (CAV). There are several types
of caveolins. CAV-1 and CAV-2 are ubiquitously expressed,
whereas CAV-3 is only expressed in muscle tissue [49]. CAV-
1 is the only member of the family required for caveolar
formation. CAV-1 acts as a tumor suppressor in breast
cancer and other tumors [50], and it is a direct EWS-
FLI1 transcriptional target [51] .I nE S F T ,C A V - 1i sak e y
determinant of tumorigenicity, which implies that it may
be a molecular target for new therapeutic strategies [51]. It
has also been proposed as a potential diagnostic marker for
ESFT [24], but this observation needs additional study for
conﬁrmation.
3.4. Markers of Neural Diﬀerentiation. As noted above, a
neural phenotype has been detected in many ESFT by
immunohistochemistryandultrastructure.In1982,Schmidt
et al. [14] noted that neural features such as processes,Sarcoma 5
dense core granules, and microtubules could be noted in
cases diagnosed as Ewing sarcoma. In 1986, Dickman and
Triche [52] established diagnostic criteria for diﬀerentiation
of extraosseous Ewing sarcoma (EOE) versus primitive
rhabdomyosarcoma by electron microscopy. In a study of
EOE treated with Intergroup Rhabdomyosarcoma Study
protocols, Shimada et al. [53] identiﬁed 14 cases as pPNET
based on neural and schwannian diﬀerentiation detected by
immunohistochemistry and ultrastructure.
Neural diﬀerentiation can be demonstrated in ESFT by
antibodies against neuron-speciﬁc enolase (NSE), CD57
(Leu-7, HNK1), S-100 [28, 29], neuroﬁlaments (NF), and
synaptophysin [54]. Schmidt et al. [27] proposed that
pPNET diagnosis could be based on two diﬀerent neural
markers; before their study, a diagnosis of pPNET was made
on only one neural marker (NSE, Leu-7, S-100, NF). Partial
neural diﬀerentiation appears to be a frequent event in
ESFT, judging from immunohistochemical and electron
microscopic studies [54].
Both ES and pPNET are forms of ESFT, diﬀering only
in extent of neuroectodermal phenotype and morphological
diﬀerentiation [18]. Literature review of older publications
indicatedanoverallsurvivalofonly30%forPNETand65%–
70% for EOE [16].
3.5. Miscellaneous Markers of Diﬀerentiation in ESFT. Pos-
itivity for various other phenotypic markers has been
reported in ESFT. Markers such as desmin [55] and cytok-
eratins [23, 24] have been described. CD99-negative small
roundcelltumorswithpolyphenotypicexpressionhavebeen
reported [56]. Katz et al. [34] reported a polyphenotypic
intraabdominal neoplasm with features of both ESFT and
DSRCT and EWS/FLI1 transcript. Thorner et al. [56]
described a DSRCT-like polyphenotypic small round cell
tumor with an EWS/ERG fusion transcript.
Sorensen et al. [57] reported t(11;22) in 1 case of
embryonal rhabdomyosarcoma and 4 cases of alveolar
rhabdomyosarcoma. This raises questions about the genetic
nature of so-called “primitive ectomesenchymomas”, lesions
with a mixed myogenic-neural phenotype. These lesions are
currently treated as rhabdomyosarcomas [58].
3.6. CD133 in Recurrent ESFT. In recent years, putative
tumor-initiating cancer stem cells (tiCSC) have been isolated
from human tumors [59]. TiCSC may be more resistant to
standard chemo- and radiation-based therapies than bulk
tumor cells [60]. CD133 has been described as putative
marker of tiCSCs in ESFT [61]. It is thus proposed that
CD133 may be a marker of chemoresistance in at least some
cases of primary ESFT [61].
4. Cytogenetics andMolecular Featuresof ESFT
Speciﬁc balanced chromosomal translocations cytogeneti-
cally characterize ESFT [45] and create aberrant chimeric
fusion oncogenes with diﬀerent transactivation activities
[62]. Currently, the gold standard for the diagnosis of
ESFT is conﬁrmation of histological diagnosis by cytoge-
netics/molecular studies. In general, tumors lacking genetic
Table 3: Translocations reported in ESFT [22, 67, 68].
Translocation Fusion gene Per cent positive
t(11;22)(q24;q12) EWS-FLI1 >85
t(21;22)(q22;q12) EWS-ERG 5–10
t(19;der)inv(21;22) EWS-ERG <1
t(7:22)(p22;q12) EWS-ETV1 <1
t(17;22)(q12;q12) EWS-ETV4 <1
t(2;22)(q33;q12) EWS-FEV <1
t(6;22)(p21;q12) EWS-POU5F1 <1
t(1;22)(q36.1;q12) EWS-PATZI <1
t(2;22)(q31;q12) EWS-SP3 <1
t(20;22)(q13;q12) EWS-NFATc2 <1
t(16;21)(p11;q22) FUS-ERG <1
t(2;16)(q35;p11) FUS-FEV <1
t(4;19)(q35;q13) CIC-DUX4 <1
conﬁrmation and signs of speciﬁc diﬀerentiation are termed
“undiﬀerentiated sarcomas” and are currently treated as
nonrhabdomyosarcomatous soft tissue sarcomas by the
Children’s Oncology Group (COG) [63].
4.1. Translocations Involving EWS (See Table 3). In 99% of
cases, molecular fusions of ESFT involve the EWS gene (also
known as EWSR1; located on chromosome 22) and a mem-
ber of the ETS family of transcription factors, which includes
FLI1 (on chromosome 11) and ERG (in chromosome 21). In
5%–10% of ESFT, EWS is fused to other ETS members such
as ETV1, ETV4,o rE1AF [64]. Although it is a promiscuous
gene that creates chimeras in a variety of neoplasms, fusions
of EWS to ETS family genes are unique to ESFT. The list of
variants of ETS family that genes may substitute for FLI1
continues to grow. Regardless of the ETS partner involved,
variant translocations do not alter the tumor phenotype
[65]. EWS fuses to non-ETS genes in other types of tumors,
such as desmoplastic small round cell tumor, angiomatoid
ﬁbrous histiocytoma, clear cell sarcoma of soft tissue, and
extraskeletal myxoid chondrosarcoma [66, 67]. Therefore,
the partner gene, rather than EWS per se, appears to specify
the tumor type.
Within the t(11;22), the chromosome breakpoint sites
varyamong4intronsinEWS geneandsixintronsintheFLI1
gene and yield a large number of possible EWS-FLI1 fusion
combinations [69]. EWS-FLI1 is the most heterogeneous
gene fusion in cancer [70]. Diﬀerent combinations of exons
from EWS and FLI1 create up to 18 possible types of in-
frame EWS-FLI1 chimeric transcripts [69]; these have been
termed “type 1”, “type 2”, and so forth, fusions. Some reports
indicate that fusion heterogeneity has functional and clinical
signiﬁcance [71]. Zoubek et al. [72] and De Alava et al. [73]
reported that respective subgroups of 55 and 99 patients
with localized ESFT and type 1 EWS-FLI1 fusions had longer
relapse-free survival than those with nontype 1 fusions.
Two more recent prospective studies [15, 72]h o w e v e r
indicatedthatwithmoreeﬀectivetherapythereisnosurvival
a d v a n t a g eo ft y p e1f u s i o n si nE S F T .6 Sarcoma
The alternate ESFT translocation t(21;22) causes a fusion
of EWS to ERG, which encodes a transcription factor highly
related to FLI1. EWS/ERG induces hematopoietic tumors in
knock-in mice, suggesting that it can operate in targets other
than mesenchymal cells [74].
With the t(2;22), t(7;22), and t(17;22) [70], EWS respec-
tively fuses to FEV, ETV1, and EIAF (additional members
of the ETS transcription factor family). These translocations
occur only rarely and have not been the subject of detailed
study. However, note that their presence would not be
detected in ESFT if only EWS/FLI1 and EWS/ERG RTPCR
were performed.
InthreereportedcasesofCD99-negativesmallroundcell
tumors resembling ESFT, EWS juxtaposes to SP3, 2NF278,
and POU5FI genes, which encode transcription factors
not been previously implicated in ESFT [75]. Although
extremely rare, lesions with the morphology and phenotypic
of polyphenotypic small round cell tumor, rhabdomyosar-
coma, or desmoplastic small round cell tumor have been
reported to contain either EWS-FLI1 [56]o rEWS-ERG
fusion genes [76].
4.2. ESFT Translocations Not Involving EWS (See Table 3).
Variant translocations involving the TET family to which
EWS belongs have also recently been described. These
“promiscuous” molecular partnerships may cause false-
negative results during diagnostic evaluation if the appro-
priate probes are not used (Figure 4)[ 70]. FUS (also a
member of the TET family of RNA-binding proteins) shows
considerably homology to EWS and rarely substitutes for
EWS in ESFT fusion formation (reviewed by Barr [70]). The
resultant t(16:21)(p11;q24) produces an FUS-ERG fusion
with no EWS rearrangement [77]. In the t(2;16)(q35;p11)
balanced translocation, there is an in-frame fusion of FUS
to FEV [78].
4.3.Translocation-NegativeESFT. SomeESFT-likecaseswith
typical morphology and immunohistochemistry may be
negative for the common translocations [70]. These lesions
constitute genuinely challenging cases, as EWS fusion neg-
ativity casts doubts about the diagnosis. Many of these
are being treated as “undiﬀerentiated sarcomas” until new
information can clarify their biologic nature.
ESFT-like tumors showing similar morphology but
lacking CD99 expression may have novel gene fusions.
A completely novel gene fusion CIL-DUX4 that does not
involve genes related to EWS or ETS family members has
been described in two cases [75]. The exact relationship of
these lesions to ESFT is undetermined.
The growing complexity of ESFT-related genetic rear-
rangements indicates that individual cases may have ESFT
morphology and phenotype but lack evidence of EWS
fusions by standard methodology [70]. As noted above,
both partner genes may be separately involved in variant
translocations [77]. Thus, a negative result generated by
genetics testing should not absolutely preclude a diag-
nosis of ESFT in the context of typical morphological
and immunophenotypic features. This situation underscores
the value of using classical karyotype analysis in sarcoma
Telemeric FUS
FUS (16p11) Centromeric FUS
Figure 4: Ewing’s sarcoma with FUS translocation. This CD99-
positive lesion arose from the femur and had typical Ewing’s
sarcoma morphology. It was negative for an EWS rearrangement
by both RT-PCR and FISH studies. In this interphase nucleus, note
that one copy of the FUS locus has been divided, as evidenced
by separate centromeric and telomeric gene signals, whereas the
other copy has an intact, conjoined signal. Since breakapart FISH
only tests a single gene locus, the partner gene in this translocation
is unknown (ﬂuorescence in situ hybridization of the FUS locus;
courtesy of Dr. Ji-Yun Lee, University of Oklahoma).
diagnosis, because of the ability of standard cytogenetics to
interrogate the cancer genome for balanced chromosomal
translocations and other genomic aberrations. On the other
hand, one should remember that other round cell sarcomas,
particularly synovial sarcoma, alveolar rhabdomyosarcoma,
and T-cell lymphoma, may closely mimic ESFT and should
be vigorously excluded in these situations.
5.Secondary GeneticChangesofESFT
Recent studies have focussed on secondary changes of ESFT,
such as mutations and epigenetic alterations, particularly as
a means of predicting clinical outcome. This work detects
molecular targets that could be used in high risk patients.
However,mostcurrentlyavailablestudiessuﬀerfromlimited
sample size, overly complex amounts of data, and lack
of multivariate analyses that consider clinical prognostic
indicators such as site, age, and stage. Nevertheless, these
recent reports oﬀer exciting glimpses into future avenues
for exploration and include studies at the DNA, RNA, and
protein level.
5.1. Comparative Genomic Hybridization. Comparative
genomic hybridization (CGH) has been used to detect
numerical gene abnormalities in ESFT [79, 80]. Numerical
abnormalities with gains in chromosomes 1q21-22, 8, and
12 have been reported [79, 80]. In a study of 62 ESFT by
CGH, univariate analysis showed that patients with gains
of chromosomes 1q, 2q, 12, and 20 or losses of 16q and
17p have signiﬁcantly lower overall survival than those
without such aberrations [81]. A separate CGH study by
Savola et al. of 31 ESFT [82] reported that the most frequent
copy changes were gains at 1q, 2, 8, and 12 and lossesSarcoma 7
at 9p and 16q. In this study, patients whose tumors had
three or fewer copy number changes had better survival
than patients with tumors having a higher number of
copy number aberrations. Expression array studies of 16
of Savola et al.’s cases identiﬁed 20 novel ESFT-associated
oncogenes and tumor suppressor genes. This study adds
new information regarding alterations in ESFT gene copy
number and provides valuable data for future analyses.
5.2. Gene Expression Proﬁles. Other expression array studies
have also yielded data of interest. Based on microarray study
of a small population of 20 metastatic and primary ESFTs,
Ohali et al. [83] claimed that gene expression at diagno-
sis might be used to predict recurrence and metastases.
In a similar study of 27 ESFT, Schaeﬀer [84] identiﬁed
genes that were diﬀerentially regulated between metastatic
and localized tumors and described characteristic gene
expression signatures associated with metastases, including
signalling pathways for activation of PDGF and WNT1,
apoptosis, angiogenesis, alteration of p53, and resistance to
chemotherapy.
The expression proﬁle of EWS/FLI in cell lines has
been modulated by use of inhibitory RNA segments (RNAi)
[85–87]. This work identiﬁes target genes of the fusion
protein and suggests that the phenotype is mediated by the
t(11;22)(q24;q12). With this model, there were 3-4 times
as many genes that were down-regulated by EWS-FLI1 as
were up-regulated. One target gene of EWS/FLI appears to
be NKX2.2, whose expression is critical for the transformed
phenotype of Ewing’s sarcoma cells. NKX2.2 plays a normal
role in central nervous system and neuronal development,
but its role in oncogenesis is unknown.
Signalling [22] and metabolic pathways [88] are being
actively investigated to identify potential candidates for
therapeutic intervention and predictive prognostic factors.
5.3. Cell Cycle Genes. Studies involving translocations have
generally overshadowed the relevance of secondary muta-
tionsinESFTbiology.However,genetic/epigeneticalteration
of factors such as p53 or p16 may determine prognosis.
p53 alterations appear to deﬁne a small clinical sunset of
ESFT with a markedly poor outcome [89, 90]. Signiﬁcant
correlation exists between a good chemotherapeutic eﬀect
(as determined by tumor necrosis) and the absence of
genetic alterations in p53 or p16/p14ARF [91]. p16 data
appear contradictory. Loss of heterozygosity of the cell cycle
regulatory gene CDKN2A (which codes for p16) has no
prognostic signiﬁcance in primary ESFT, suggesting no role
for epigenetic modiﬁcation of this gene [92]. High levels of
p16/p14ARF mRNA predict poor event-free survival, but the
results need further conﬁrmation [92]. The inconsistency
of data obtained by proﬁling p16 and p14ARF gene status,
mRNA, and protein expression emphasizes the importance
of investigating cell cycle regulatory genes in identical
clinicalsamples,usingstandardizedmethods,andemploying
a prospective clinical outcome study. Data regarding p53
pathway impairment and poor ESFT prognosis suggests that
this parameter should be investigated in future prospective
studies to determine whether it should be added to routine
staging analyses. Increased Ki-67 expression has also been
reported as a valuable indicator of poor prognosis in
localized ESFT [93].
5.4. Microsatellite Instability. Microsatellite instability (MI)
has been of great interest in human cancer, particularly
colon carcinoma. The prevalence of MI in ESFT and how
this factor relates to prognosis are not clear. Aldinger et al.
[94] retrospectively analyzed MI in ESFT and concluded that
loss of mismatch repair protein expression is not prevalent
in ESFT, but the nature of that instability diﬀers from the
form observed in colorectal carcinoma. Microsatellites have
been found to be responsive elements to EWS-FLI1 [22,
95, 96]. EWS-FLI1 interacts with GGAA-microsatellites to
regulate some target genes, including NROB1,a nE W S - F L I 1 -
regulated gene that is required for the oncogenic phenotype
of ESFT [97].
6. Ontogenesis of ESFT
Since James Ewing in 1921 ﬁrst described a diﬀuse heman-
gioendothelioma of bone [1], several studies have attempted
to elucidate the histogenesis of ESFT (reviewed by Yunis
[17]). Initial morphological and immunopathological data
suggested that ESFTs arise from primary mesenchymal
stem cells with potential for multilineage diﬀerentiation
[40]. The expression of neural markers in ESFT suggests
either a neuroectodermal origin or a potential mesenchymal
cell origin with secondary expression of a partial neural
phenotype.
Several recent articles focusing on expression proﬁles of
ESFT cell lines have given new clues on molecular mecha-
nisms related to the origin, development, and progression
of ESFT [79–87]. A large number of EWS/FLI1 target genes
have been identiﬁed, some of which are upregulated and
others are downregulated.
Mesenchymal stemcells (MSCs) are currently considered
strong candidates for the cell of origin of ESFT [20, 98, 99].
Among primary human cells, only MSCs display permis-
siveness for stable EWS-FLI1 expression without undergoing
growth arrest [20, 98]. In cell cultures, EWS-FLI1 behaves
as an aberrant transcription factor that transforms MSCs by
deregulating their gene expression [98]. In human pediatric
MSCs(hpMSC),EWS-FLI1inducestheexpressionofembry-
onic stem cell genes OCT4, SOX2,a n dNANOG [100]a n d
numerous genes involved in neural and neuroectodermal
diﬀerentiation. In special media, transfection of EWS/FLI1
and repression of the inhibitory eﬀect of miRNA cause
hpMSC to assume a neural crest stem cell phenotype and to
generate a subpopulation of cells that display ESFT features
[100]. The target gene SOX2 appears to be a key player
in determining ESFT cell diﬀerentiation and tumorigenicity
[100].
The expression of neural markers in ESFT has also been
intensely investigated. In 2005, Hu-liekovan [101] showed
that EWS-FLI1 has a profound eﬀect on cell diﬀerentiation
as well as proliferation. They hypothesized that EWS-FLI1
acts as a lineage determinator rather than a pure oncogene,
and they speculated that ESFT probably originates from8 Sarcoma
primitive multipotent progenitor cells that are capable
of diﬀerentiating into neural crest derivatives. EWS-FLI1
subsequently may impose a neural crest parasympathetic
direction to the cells, but it inhibits terminal diﬀerentiation.
Eventual secondary genetic alterations may be the oncogenic
events that lead to cancer.
Baliko et al. in 2007 [102] showed that Notch signalling
is active in ESFT tumors and cell lines, which express
Notch receptors, ligands, and the Notch target gene HES1.
Notch signalling inhibition causes ES cells to assume a
more diﬀerentiated neuroid phenotype, also supporting
the notion that ESFTs are derived from neuroectodermal
precursors whose diﬀerentiation is inhibited by oncogenesis.
Notch signalling inhibition induces neural diﬀerentiation
but eﬀects only minor changes in tumor growth, suggesting
that it should not aﬀect clinical outcome [29, 54, 103].
In 2010 [104] Gayscone reported that the neuronal
markerBRN3Aisexpressedabundantlyattheproteinlevelin
primary ESFT but not in neuroblastoma or rhabdomyosar-
coma. Therefore, it appears that EWS/ETS proteins induce
expression of neuronal markers and stimulate early stages of
neuronal development but prevent terminal neuronal diﬀer-
entiation.EWS/ETSmayregulateneuronaldiﬀerentiationby
controlling selective BRN3A transcriptional function.
7. Predictive Prognostic Factors in ESFT
A variety of predictive factors have been linked to survival of
ESFT patients. These include clinical factors as well as the
biological markers discussed above. The following section
outlines our current understanding of prognostic factorsand
puts them into a clinical context.
7.1. Metastases. Presence of metastases is the most promi-
nent adverse prognostic factor in ESFT; patients presenting
with metastatic tumor have an estimated survival of only 20–
25%. [19, 105–109]. Recurrence after therapy also portends
a dismal outcome [110]. Recently, it has been reported that
patients with primary disseminated multifocal ESFT may
survive with intensive multimodal therapy [111].
Site of metastasis appears to be an important prog-
nostic factor in MD. Patients with primary pulmonary
metastases fare better than those with nonpulmonary tumor
spread, especially following bilateral lung irradiation or
myeloablative high-dose therapy (HDT) [107, 111–114],
as compared to patients with primary bone and/or bone
marrow involvement [108, 111, 113, 115–117].
In the Euro-Ewing 99 trial for patients with disseminated
multifocal ESFT (excluding those with isolated pulmonary
metastases) [111], increased risk was associated with the
number of skeletal metastatic lesions. Of patients with more
than 5 metastatic lesions at diagnosis, only 16% survived.
7.2. Localized Disease. Because of their higher survival rate,
patients with localized disease at diagnosis oﬀer a better
opportunity to study prognostic factors in ESFT. In these
patients, cooperative group and single institution studies
have associated adverse outcome with older age at presenta-
tion (≥14 years [114, 118]o r≥18 years [106]), large tumor
volume [119], poor response to induction therapy [120],
axial location [114, 120], elevated LDH [121], secondary
genetic abnormalities [122], deletion of p16 [123], and
mutation of P53 [89, 90]. Prediction results vary widely
amongstudies;theyuseddiﬀerentcriteria(e.g.,alargetumor
may be deﬁned as one >100mL, >200mL, or >8cm) and
treatments.
7.3. Age. The impact of age on the prognosis of ESFT
remains controversial [124]. In diﬀerent studies, the cut oﬀ
forageanalysisisvariable:14[114,117],15[108],or18years
[106]. Ferrari [125] stratiﬁed ages as up to 14y, from 15 to
18y,and>18y.Incertainseries,olderagehasbeenassociated
with inferior clinical outcome [106–108, 126], yet others
have been unable to demonstrate a signiﬁcant diﬀerence
based on age alone [114, 124, 127, 128]. The impact of
age can be confounded by the greater proportion of large
pelvic primary tumours and more advanced disease in adult
patients, and speciﬁc biological diﬀerences may also play a
role [108, 124]. Older age remains an adverse prognostic
factor despite the addition of ifosfamide and etoposide to the
therapeutic regimen [106]. In a study to assess the impact of
diﬀerent therapies in children and adults, Gupta et al. [124]
reported that adults with localized ESFT had an inferior
outcome compared to pediatric patients, possibly due to
dosage of alkylating agents and timing of local therapy.
7.4. Gender. Gender of patients is not signiﬁcantly related to
ESFT survival [106, 129].
7.5.Size(TumorVolume). Classically,largetumorshavebeen
associated with a worse prognosis. The size of the tumors has
beenassessedby longitudinal andvolumetric measurements.
Tumors greater than 8cm are associated with a worse
prognosis by univariate analysis [118, 130]. However, tumor
size disappeared as a prognostic factor in the more intensive
EW92 protocol [131]. In the CESS81 study, tumors greater
than 100cm3 were originally associated with worse outcome
by univariate analysis [115]. However, with subsequent
treatment improvements, the tumor size associated with a
worse prognosis increased to greater than 200cm3 [119]. In
a multivariate analysis, Lee [129] reported that metastatic
diseaseandlargetumorsizeremainedindependentpredictor
factors, while pelvic involvement did not.
EICESS-92. the largest attempt to stratify ESFT therapy
on the basis of tumor size [132] found no diﬀerence in
survival between standard risk (localized small tumors) and
high risk (large localized tumors or patients with metastatic
disease) patients receiving standard therapy. Patients in the
high risk arm with large localized tumors showed a trend
toward improvement with the addition of etoposide, but this
trenddidnotreachstatisticalsigniﬁcance[132,133].Because
patients with metastases were in the same risk group as those
with large tumors, the results cannot be interpreted based on
size alone [133].
Primary tumor volume is a strong independent prog-
nostic factor, even in patients with primary disseminated
multifocal ESFT, and is more important than site of primarySarcoma 9
tumor. A trend toward worse outcome for central tumors
has been seen, which may reﬂect problems in local control
[111]. Larger tumor size will always represent a therapeutic
challenge because of the problems with local control. How-
ever, without more standardized criteria for assessment of
tumor size (longitudinal versus volumetric measurements),
the value of volume as a prognostic factor will be imperfect
[118].
7.6. Site. Axial tumors showed more aggressive behaviour
in the early IESS (IESS-I) [134] and UKCCSG/MRC (ET-
1) [107] studies. However, the same cooperative groups
reported minimal or insigniﬁcant diﬀerences in outcome
based on site (IESS-II and ET-2) [118, 135, 136]. The
ﬁrstPOG-CCGEwingtrial(POG-8850/CCG-7881)reported
that addition of ifosfamide-etoposide to the standard VACD
regimen abrogated the negative prognostic implications of
large tumor size (>8cm) and pelvic location [118, 137].
Multivariate analysis has been controversial. Some studies
have found pelvic location and time to local therapy to be
associated with outcome [124], while other studies [129]
reported that pelvic involvement was not independently
associated with risk of death.
The increased prevalence of pelvic ESFT in adult patients
is often cited as one of the main contributors to poor
outcome [124]. It is likely that pelvic tumors are diagnosed
later than tumors of the extremities because of subclinical
extension into the pelvic cavity. This factor is consistent
with the greater tumor volume of pelvic tumors and their
signiﬁcantly higher proportion of metastases at diagnosis
[109, 129].
7.7. Neural Diﬀerentiation. The eﬀect of neural diﬀerenti-
ation on ESFT behaviour has been a source of conﬂicting
results. For this purpose, ES must be consistently separated
frompPNET,buttumoralheterogeneitymakesthisadiﬃcult
task. In spite of initial enthusiasm for neural diﬀerentiation
asaprognosticfactor(reviewedbyDehner[16]),subsequent
retrospective studies have found it has no signiﬁcant impact
on clinical behaviour [28, 29, 103, 138].
Of interest, however, is the observation that outcome of
osseous and extraosseous ESFTs did not diﬀer in a recent
Children’s Oncology Group study [139]. An unpublished
analysis of osseous ESFT patients by the Children’s Cancer
Study Group and Pediatric Oncology Group found that in
nonmetastatic patients, neural diﬀerentiation even oﬀered
a survival advantage [140]. Similarly, Parham et al. [54]i n
1999 found that neuroectodermal diﬀerentiation did not
predict tumor behaviour in a retrospective study of 60 cases
treated by modern therapy in two large institutions. They
suggested that with improved multiagent chemotherapy,
surgery, and radiation, diﬀerences in outcome between
pPNET and ES no longer exist. This was also been reported
in other studies [103]. Because of these conﬂicting results,
current studies no longer separate ES from pPNET for
prognostication or treatment.
However,Baccietal.in2000[141]indicatedthatpatients
with PNET of bone fare signiﬁcantly worse than patients
with classical ES. Of note, cytogenetic results were not
included in this study, and the same authors made no claims
regarding neural diﬀerentiation in two subsequent outcome
analyses of nonmetastatic ESFT [141, 142].
Atypical ESFT has been recently claimed in retrospective
study to be the only histological variety associated with a less
favourable clinical outcome [24], although this was not the
case in the initial reports [10, 11].
7.8. Chemotherapy Response. During the past 30 years,
improvements in systemic and local therapies have increased
survival from less than 5% overall to 65%–70% for localized
ESFTandto25%–30%formetastatictumors[114,118,143].
Alkylating agents (ifosfamide and cyclophosphamide) and
anthracyclines (doxorubicin) are the two groups of agents
most eﬀective against ESFT. High-risk patients seem to
have beneﬁted from intensiﬁed treatment that incorporated
ifosfamide [106, 117, 119].
Current chemotherapy regimens use the same drugs
(vincristine, doxorubicin, cyclophosphamide, ifosfamide,
and etoposide), although the exact regimen diﬀers between
Europe and North America [19, 105, 144]. Chemother-
apy dose intensiﬁcation and the use of megatherapy with
autologous hematopoietic stem cell transplant seem valid
alternatives for high risk patients.
Many factors can aﬀect the feasibility, modalities,
and timing of proposed treatments. Factors aﬀecting the
pharmacokinetics of cancer chemotherapy have important
consequences in terms of therapeutic eﬃcacy and safety.
Cytochrome P450 [145] plays an important role in the
biotransformation of anticancer agents [146] and metabo-
lizes cyclophosphamide and ifosfamide. Factors such as age,
genetic polymorphism, and intake of drugs and food can
modify the activity of cytochrome P450, [147]. An inﬂuence
of age on pharmacokinetics of ifosfamide has been reported
[148].
Scotlandi (2009) [149] analysed the molecular factors
that reﬂect tumor resistance to chemotherapy in ESFT and
found that glutathione metabolism is a major pathway
regulatingESFTchemoresistance.GlutathioneS-transferases
(GSTs) are a family of detoxiﬁcation enzymes that catalyze
the conjugation of glutathione to a wide variety of endoge-
nous and exogenous compounds. GSTs have been implicated
in the development of resistance toward chemotherapeu-
tic agents [150]. Low expression of MGST1 (microsomal
glutathione S-transferase 1) is signiﬁcantly associated with
better prognosis.
7.9. Chemotherapy-Induced Necrosis. In patients treated with
primary chemotherapy followed by surgical excision, assess-
ment of chemotherapy-induced necrosis allows reliable
evaluation of tumor chemosensitivity. Good histological
response is strongly related to good clinical outcome [119,
125, 126, 128] .T h ed e g r e eo fn e c r o s i ss e e m st ob ei n d e -
pendent of the drugs used and the length of preoperative
chemotherapy [125]. Histological response is determined by
the method of Salzer-Kuntschick et al. [151], in which 10%
or fewer viable tumor cells in the surgical specimen are
classiﬁed as “good response” and greater that 10% viability
is regarded as “poor.” Ferrari et al. (2007) [125]i n v e s t i g a t e d10 Sarcoma
the inﬂuence of traditional factors (age, sex, site and size
of the tumor, fever, and lactate dehydrogenase levels) on
histological response of nonmetastatic ESFT; age and sex
appear to inﬂuence the degree of necrosis.
8. Conclusions
Progress in the treatment of ESFT in the last three decades
hasderivedlargelyfromAmericanandEuropeancooperative
trials using chemotherapy intensiﬁcation and improved local
control [19, 105, 118, 152]. Chemotherapy intensiﬁcation
and optimal local control have overcome diﬀerences in
classical clinical, and biological prognostic factors that for-
merly portended a poor outcome [105]. With most modern
treatment regimens, the disease-free survival for patients
with localized disease may approach 70%, while overall
survivalmayexceed80%[19,105,117,118].However,a30%
relapse rate is still unacceptably high, considering that most
relapsed patients do not survive [153].
The improvement of ESFT therapy is linked to the
discovery of new strategies to select patients with poor and
good prognosis. In the COG studies in North America, there
are 3 risk groups: patients with localized tumours, patients
with lung metastases only, and patients with other multiple
metastases. Euro E.W.I.N.G. 99 study uses metastatic sites
(none, lung, or other) and initial tumor size (< or >
than 200mL) for initial stratiﬁcation and subsequently
considers resectability and histological response to initial
chemotherapy to assign patients to treatment randomization
[144]. Therefore, excepting metastases at diagnosis, tumor
burden, and response to chemotherapy, little is known about
factors that determine disease progression or relapse [19].
Drug-resistant disease remains a major cause of mor-
tality among patients diagnosed with ESFT. An improved
understanding of the mechanisms of drug resistance and
discovery of biomarkers associated with chemoresistance are
needed for improved treatment of ESFT patients. Molecular
signatures [149]o ﬀer a novel means of classiﬁcation of ESFT
patients into high- and low-risk groups, The glutathione
metabolism pathway has emerged as one of the most signif-
icant pathways associated with prognosis. A small molecule
inhibitor of GST enzymes 6-(7-nitro-2, 1, 3-benzoxadiazol-
4-ylthio) hexanol NBDHEX has been proposed as a new
potential therapeutic agent [149, 154].
The elucidation of the cell of origin is a crucial issue
for discovering the mechanisms involved in the genesis of
ESFT and for identiﬁcation of reliable molecular markers
and possible therapeutic agents. Mesenchymal stem cells or
progenitor cells are currently considered strong candidates
as the cell of origin of ESFT [20, 98, 99].
Preliminary data suggest that assessment of CD133
or Ki67 expression in diagnostic biopsies may identify
tumors with poor outcome [61, 93], but conﬁrmation is
needed. The claim that atypical ES is associated with less
favourable outcome needs to be tested in future trials, using
clear-cut, reproducible criteria. The pathological criteria to
diﬀerentiateESversuspPNETalsoneedtobeclearlydeﬁned,
so that we can establish strict criteria for diagnosis that
permit reliable assessment of these features. Future research
in the histopathological characterization of ESFT is thus
warranted.
Eﬀorts are ongoing to deﬁne the mechanisms of tumori-
genesis molecular interactions of EWS/FLI1. Target genes
that may be accessible for therapeutic agents are receptor
tyrosine kineses, histone deacetylases, heat shock proteins,
a n dm T O Rd e r i v a t i v e s[ 144, 153, 155].
Secondary mutations that could be of relevance in the
biology of ES have often been usually overshadowed by
studies of translocations. Secondary events could have rele-
vance not only for prognosis but also for understanding the
steps involved in cell transformation. Losses of p161INK4A,
mutation of TP53, and deletion of CKDN2A appear to
correlate with a poor prognosis [90, 91, 123]. Several groups
[22, 115, 156] have identiﬁed gains and losses of various
chromosomes that may be associated with a poor prognosis
[82]. However, none of these parameters has been tested
prospectively in a meaningful cohort of patients.
In summary, a better understanding of the molecular
pathogenesis and biology of ESFT is leading to a new
deﬁnition of potential targets for antitumour therapy. As the
regulatory pathways responsible for transformation, growth,
and metastases of ESFT become more deﬁned, potentials
for new therapeutic targets will expand. This situation has
created both a challenge and an opportunity to develop
predictive biomarkers capable of selecting patients most
likely to beneﬁt from targeted therapy.
References
[1] J. Ewing, “Diﬀuse endothelioma of bone,” Proceedings of the
New York Pathology Society, vol. 21, pp. 17–24, 1921.
[2] R. Moll, V. E. Gould, and R. Berndt, “Immunocytochemical
analysisofEwing’stumors.Patternsofexpressionofinterme-
diate ﬁlaments and desmosomal proteins indicate cell type
heterogeneity and pluripotential diﬀerentiation,” American
Journal of Pathology, vol. 127, no. 2, pp. 288–304, 1987.
[ 3 ]A .O .C a v a z z a n a ,J .S .M i s e r ,J .J e ﬀe r s o n ,a n dT .J .T r i c h e ,
“Experimental evidence for a neural origin of Ewing’s
sarcoma of bone,” American Journal of Pathology, vol. 127,
no. 3, pp. 507–518, 1987.
[4] M. Lipinski, K. Braham, and I. Philip, “Neuroectoderm-
associated antigens on Ewing’s sarcoma cell lines,” Cancer
Research, vol. 47, no. 1, pp. 183–187, 1987.
[5] M. Lipinski, M.-R. Hirsch, and H. Deagostini-Bazin, “Char-
acterization of neural cell adhesion molecules (NCAM)
expressed by ewing and neuroblastoma cell lines,” Interna-
tional Journal of Cancer, vol. 40, no. 1, pp. 81–86, 1987.
[6] K. Kawaguchi and M. Koike, “Neuron-speciﬁc enolase
and Leu-7 immunoreactive small round-cell neoplasm: the
relationship to Ewing’s sarcoma in bone and soft tissue,”
American Journal of Clinical Pathology, vol. 86, no. 1, pp. 79–
83, 1986.
[7] A. Llombart-Bosch, M. J. Lacombe, G. Contesso, and A.
Peydro-Olaya, “Small round blue cell sarcoma of bone
mimicking atypical Ewing’s sarcoma with neuroectodermal
features. An analysis of ﬁve cases with immunohistochemical
and electron microscopic support,” Cancer,v o l .6 0 ,n o .7 ,p p .
1570–1582, 1987.
[8] A. P. Stout, “A tumor of the ulnar nerve,” Proceedings of the
New York Pathology Society, vol. 18, pp. 2–12, 1918.Sarcoma 11
[9] L. Angervall and F. M. Enzinger, “Extraskeletal neoplasm
resembling Ewing’s sarcoma,” Cancer, vol. 36, no. 1, pp. 240–
251, 1975.
[10] E. H. Soule, W. Newton Jr., T. E. Moon, and M. Teﬀt,
“Extraskeletal Ewing’s sarcoma. A preliminary review of
26 cases encountered in the intergroup rhabdomyosarcoma
study,” Cancer, vol. 42, no. 1, pp. 259–264, 1978.
[11] A. G. Nascimento, K. L. Cooper, and K. K. Unni, “A
clinicopathologic study of 20 cases of large-cell (atypical)
Ewing’s sarcoma of bone,” American Journal of Surgical
Pathology, vol. 4, no. 1, pp. 29–36, 1980.
[12] F. B. Askin, J. Rosal, and R. K. Sibley, “Malignant small cell
tumor of the thoracopulmonary region in childhood. A dis-
tinctive clinicopathologic entity of uncertain histogenesis,”
Cancer, vol. 43, no. 6, pp. 2438–2451, 1979.
[13] R. Jaﬀe, M. Santamaria, and E. J. Yunis, “The neuroectoder-
mal tumor of bone,” American Journal of Surgical Pathology,
vol. 8, no. 12, pp. 885–898, 1984.
[14] D. Schmidt, B. Mackay, and A. G. Ayala, “Ewing’s sarcoma
with neuroblastoma-like features,” Ultrastructural Pathology,
vol. 3, no. 2, pp. 143–151, 1982.
[15] L. P. Dehner, “Peripheral and central primitive neuroecto-
dermal tumors. A nosologic concept seeking a consensus,”
Archives of Pathology and Laboratory Medicine, vol. 110, no.
11, pp. 997–1005, 1986.
[16] L. P. Dehner, “Primitive neuroectodermal tumor and Ewing’s
sarcoma,” American Journal of Surgical Pathology, vol. 17, no.
1, pp. 1–13, 1993.
[17] E. J. Yunis, “Ewing’s sarcoma and related small round
cell neoplasms in children,” American Journal of Surgical
Pathology, vol. 10, pp. 54–62, 1986.
[18] S. Navarro, A. O. Cavazzana, A. Llombart-Bosch, and T.
J. Triche, “Comparison of Ewing’s sarcoma of bone and
peripheral neuroepithelioma: an immunocytochemical and
ultrastructural analysis of two primitive neuroectodermal
neoplasms,” Archives of Pathology and Laboratory Medicine,
vol. 118, no. 6, pp. 608–615, 1994.
[19] M. C. Le Deley, O. Delattre, K. L. Schaefer et al.,
“Impact of EWS-ETS fusion type on disease progression
in Ewing’s sarcoma/peripheral primitive neuroectodermal
tumor: prospective results from the cooperative Euro-
E.W.I.N.G. 99 trial,” Journal of Clinical Oncology, vol. 28, no.
12, pp. 1982–1988, 2010.
[20] N.Riggi,L.Cironi,P.Proveroetal.,“DevelopmentofEwing’s
sarcoma from primary bone marrow-derived mesenchymal
progenitor cells,” Cancer Research, vol. 65, no. 24, pp. 11459–
11468, 2005.
[21] F.Tirode,K.Laud-Duval,A.Prieur,B.Delorme,P.Charbord,
and O. Delattre, “Mesenchymal stem cell features of ewing
tumors,” Cancer Cell, vol. 11, no. 5, pp. 421–429, 2007.
[22] J. L. Ord´ o˜ n e z ,D .O s u n a ,D .H e r r e r o ,E .D e´ Alava, and
J. Madoz-G´ urpide, “Advances in Ewing’s sarcoma research:
where are we now and what lies ahead?” CancerResearch, vol.
69, no. 18, pp. 7140–7150, 2009.
[23] A. L. Folpe, J. R. Goldblum, B. P. Rubin et al., “Morphologic
and immunophenotypic diversity in Ewing family tumors: a
study of 66 genetically conﬁrmed cases,” American Journal of
Surgical Pathology, vol. 29, no. 8, pp. 1025–1033, 2005.
[24] A. Llombart-Bosch, I. Machado, S. Navarro et al., “Histolog-
ical heterogeneity of Ewing’s sarcoma/PNET: an immunohis-
tochemical analysis of 415 genetically conﬁrmed cases with
clinical support,” Virchows Archiv, vol. 455, no. 5, pp. 397–
411, 2009.
[25] P. S. Dickman, “Electron microscopy for diagnosis of tumors
in children,” Perspectives in pediatric pathology, vol. 9, pp.
171–213, 1987.
[26] J. M. Kissane, F. B. Askin, and M. Foulkes, “Ewing’s sarcoma
of bone: clinicopathologic aspects of 303 cases from the
Intergroup Ewing’s Sarcoma Study,” Human Pathology, vol.
14, no. 9, pp. 773–779, 1983.
[27] D. Schmidt, C. Herrmann, H. Jurgens, and D. Harms,
“Malignant peripheral neuroectodermal tumor and its nec-
essary distinction from Ewing’s sarcoma: a report from the
Kiel Pediatric Tumor Registry,” Cancer, vol. 68, no. 10, pp.
2251–2259, 1991.
[28] A. Pinto, L. H. Grant, F. A. Hayes, M. J. Schell, and D.
M. Parham, “Immunohistochemical expression of neuron-
speciﬁc enolase and Leu 7 in Ewing’s sarcoma of bone,”
Cancer, vol. 64, no. 6, pp. 1266–1273, 1989.
[29] M. Ladanyi, F. S. Heinemann, A. G. Huvos, P. H. Rao,
Q. Chen, and S. C. Jhanwar, “Neural diﬀerentiation in
small round cell tumors of bone and soft tissue with the
translocation t(11;22)(q24;q12): an immunohistochemical
study of 11 cases,” Human Pathology, vol. 21, no. 12, pp.
1245–1251, 1990.
[30] J .A.Bridge,M.E.Fidler ,J .R.N eﬀetal.,“Adamantinoma-like
Ewing’s sarcoma: genomic conﬁrmation, phenotypic drift,”
AmericanJournalofSurgicalPathology,vol.23,no.2,pp.159–
165, 1999.
[ 3 1 ]M .K a n a m o r i ,C .R .A n t o n e s c u ,M .S c o t te ta l . ,“ E x t r a
copies of chromosomes 7, 8, 12, 19, and 21 are recurrent in
Adamantinoma,” Journal of Molecular Diagnostics, vol. 3, no.
1, pp. 16–21, 2001.
[32] F. M. Enzinger and S. W. Weiss, Soft Tissue Tumors,M o s b y ,
St. Louis, Mo, USA, 1st edition, 1983.
[33] A. O. Cavazzana, V. Ninfo, J. Roberts, and T. J. Triche,
“Peripheral neuroepithelioma: alightmicroscopic, immuno-
cytochemical, and ultrastructural study,” Modern Pathology,
vol. 5, no. 1, pp. 71–78, 1992.
[34] R. L. Katz, M. Quezado, A. M. Senderowicz, L. Villalba, W.
B. Laskin, and M. Tsokos, “An intra-abdominal small round
cell neoplasm with features of primitive neuroectodermal
and desmoplastic round cell tumor and a EWS/FLI-1 fusion
transcript,” Human Pathology, vol. 28, no. 4, pp. 502–509,
1997.
[35] T. J. Triche, F. B. Askin, and J. Kissane, “Neuroblastoma,
Ewing’s sarcoma, and the diﬀerential diagnosis of small-,
round-, blue-cell tumors,” in Major Problems in Pathology:
Pathology of Neoplasia in Children and Adolescents,M .
Finegold, Ed., pp. 145–195, WB Saunders, Philadelphia, Pa,
USA, 1986.
[36] S. Williams, D. M. Parham, and J. J. Jenkins III, “Peripheral
neuroepithelioma with ganglion cells: report of two cases
and review of the literature,” Pediatric and Developmental
Pathology, vol. 2, no. 1, pp. 42–49, 1999.
[37] S. R. Knezevich, G. Hendson, J. A. Mathers et al., “Absence
of detectable EWS/FLI1 expression after therapy-induced
neural diﬀerentiation in Ewing sarcoma,” Human Pathology,
vol. 29, no. 3, pp. 289–294, 1998.
[38] A. J. Stevenson, J. Chatten, F. Bertoni et al., “CD99
(p30/32MIC2) neuroectodermal/Ewing’s sarcoma antigen as
an immunohistochemical marker: review of more than 600
tumors and the literature experience,” Applied Immunohisto-
chemistry, vol. 2, no. 2, pp. 231–240, 1994.
[39] A. L. Folpe, C. E. Hill, D. M. Parham, P. A. O’Shea, and S.
W. Weiss, “Immunohistochemical detection of FLI-1 protein12 Sarcoma
expression: a study of 132 round cell tumors with emphasis
on CD99-positive mimics of Ewing’s sarcoma/primitive neu-
roectodermal tumor,” American Journal of Surgical Pathology,
vol. 24, no. 12, pp. 1657–1662, 2000.
[40] D. M. Parham, “Ewing’s sarcoma, peripheral neuroepithe-
lioma, and related tumors,” in Pediatric Neoplasia: Morphol-
ogy and Biology, D. M. Parham, Ed., pp. 65–85, Raven Press,
New York, NY, USA, 1996.
[41] H. Kovar, M. Dworzak, S. Strehl et al., “Overexpression of
the pseudoautosomal gene MIC2 in Ewing’s sarcoma and
peripheralprimitiveneuroectodermaltumor,”Oncogene,vol.
5, no. 7, pp. 1067–1070, 1990.
[42] V. Cerisano, Y. Aalto, S. Perdichizzi et al., “Molecular mecha-
nisms of CD99-induced caspase-independent cell death and
cell-cell adhesion in Ewing’s sarcoma cells: actin and zyxin
as key intracellular mediators,” Oncogene, vol. 23, no. 33, pp.
5664–5674, 2004.
[43] A. R. Schenkel, E. M. Dufour, T. W. Chew, E. Sorg, and
W. A. Muller, “The murine CD99-related molecule CD99-
like 2 (CD99L2) is an adhesion molecule involved in the
inﬂammatory response,” Cell Communication and Adhesion,
vol. 14, no. 5, pp. 227–237, 2007.
[44] A. Rocchi, M. C. Manara, M. Sciandra et al., “CD99 inhibits
neural diﬀerentiation of human Ewing sarcoma cells and
thereby contributes to oncogenesis,” The Journal of Clinical
Investigation, vol. 120, no. 3, pp. 668–680, 2010.
[45] O. Delattre, J. Zucman, B. Plougastel et al., “Gene fusion
with an ETS DNA-binding domain caused by chromosome
translocation in human tumours,” Nature, vol. 359, no. 6391,
pp. 162–165, 1992.
[46] A. D. Sharrocks, A. L. Brown, Y. Ling, and P. R. Yates,
“The ETS-domain transcription factor family,” International
Journal of Biochemistry and Cell Biology, vol. 29, no. 12, pp.
1371–1387, 1997.
[47] G.Nilsson,M.Wang,J.Wejde,A.Kreicbergs,andO.Larsson,
“Detection of EWS/FLI-1 by immunostaining. An adjunctive
tool in diagnosis of Ewing’s sarcoma and primitive neu-
roectodermal tumour on cytological samples and paraﬃn-
embedded archival material,” Sarcoma, vol. 3, no. 1, pp. 25–
32, 1999.
[48] A. Llombart-Bosch and S. Navarro, “Immunohistochemical
detection of EWS and FLI-1 proteins in ewing sarcoma
andprimitiveneuroectodermaltumors:comparativeanalysis
with CD99 (MIC-2) expression,” Applied Immunohistochem-
istry and Molecular Morphology, vol. 9, no. 3, pp. 255–260,
2001.
[49] E. J. Smart, G. A. Graf, M. A. McNiven et al., “Caveolins,
liquid-ordered domains, and signal transduction,” Molecular
and Cellular Biology, vol. 19, no. 11, pp. 7289–7304, 1999.
[50] T. M. Williams and M. P. Lisanti, “Caveolin-1 in oncogenic
transformation, cancer, and metastasis,” American Journal of
Physiology, vol. 288, no. 3 57-3, pp. C494–C506, 2005.
[51] O. M. Tirado, S. Mateo-Lozano, J. Villar et al., “Caveolin-1
(CAV1)isatargetofEWS/FLI-1andakeydeterminantofthe
oncogenicphenotypeandtumorigenicityofEwing’ssarcoma
cells,” Cancer Research, vol. 66, no. 20, pp. 9937–9947, 2006.
[52] P. S. Dickman and T. J. Triche, “Extraosseous Ewing’s
sarcoma versus primitive rhabdomyosarcoma: diagnostic
criteria and clinical correlation,” Human Pathology, vol. 17,
no. 9, pp. 881–893, 1986.
[53] H. Shimada, W. A. Newton Jr., E. H. Soule, S. J. Qualman,
C. Aoyama, and H. M. Maurer, “Pathologic features of
extraosseous Ewing’s sarcoma: a report from the intergroup
rhabdomyosarcoma study,” Human Pathology, vol. 19, no. 4,
pp. 442–453, 1988.
[ 5 4 ]D .M .P a r h a m ,Y .H i j a z i ,S .M .S t e i n b e r ge ta l . ,“ N e u r o e c t o -
dermal diﬀerentiation in Ewing’s sarcoma family of tumors
does not predict tumor behavior,” Human Pathology, vol. 30,
no. 8, pp. 911–918, 1999.
[55] D. M. Parham, P. Dias, D. R. Kelly, J. C. Rutledge, and P.
Houghton, “Desmin positivity in primitive neuroectodermal
tumorsofchildhood,”AmericanJournalofSurgicalPathology,
vol. 16, no. 5, pp. 483–492, 1992.
[56] P. Thorner, J. Squire, S. Chilton-MacNeill et al., “Is the
EWS/FLI-1 fusion transcript speciﬁc for Ewing sarcoma and
peripheral primitive neuroectodermal tumor? A report of
four cases showing this transcript in a wider range of tumor
types,” American Journal of Pathology, vol. 148, no. 4, pp.
1125–1138, 1996.
[57] P.H.B.Sorensen,H.Shimada,X.F.Liu,J.F.Lim,G.Thomas,
and T. J. Triche, “Biphenotypic sarcomas with myogenic and
neural diﬀerentiation express the Ewing’s sarcoma EWS/FLI1
fusion gene,” Cancer Research, vol. 55, no. 6, pp. 1385–1392,
1995.
[58] D. R. Bou´ e, D. M. Parham, B. Webber, W. M. Crist, and S. J.
Qualman, “Clinicopathologic study of ectomesenchymomas
from intergroup rhabdomyosarcoma study groups III and
IV,” Pediatric and Developmental Pathology,v o l .3 ,n o .3 ,p p .
290–300, 2000.
[59] B.J.P.HuntlyandD.G.Gilliland,“Cancerbiology:summing
up cancer stem cells,” Nature, vol. 435, no. 7046, pp. 1169–
1170, 2005.
[60] M.-L. Suv` a, N. Riggi, J.-C. Stehle et al., “Identiﬁcation of
cancer stem cells in Ewing’s sarcoma,” Cancer Research, vol.
69, no. 5, pp. 1776–1781, 2009.
[61] X. Jiang, Y. Gwye, D. Russell et al., “CD133 expression in
chemo-resistant Ewing sarcoma cells,” BMC Cancer, vol. 10,
article 116, 2010.
[62] “Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 40-1981,” The New Eng-
land Journal of Medicine, vol. 305, no. 14, pp. 814–823, 1981.
[63] S. L. Spunt, S. X. Skapek, and C. M. Coﬃn, “Pediatric
nonrhabdomyosarcoma soft tissue sarcomas,” Oncologist,
vol. 13, no. 6, pp. 668–678, 2008.
[64] E. De Alava and W. L. Gerald, “Molecular biology of the
Ewing’s sarcoma/primitive neuroectodermal tumor family,”
JournalofClinicalOncology,vol.18,no.1,pp.204–213,2000.
[65] J. P. Ginsberg, E. De Alava, M. Ladanyi et al., “EWS-FLI1 and
EWS-ERG gene fusions are associated with similar clinical
phenotypesinEwing’ssarcoma,”JournalofClinicalOncology,
vol. 17, no. 6, pp. 1809–1814, 1999.
[66] F. Mertens, C. R. Antonescu, P. Hohenberger et al.,
“Translocation-related sarcomas,” Seminars in Oncology, vol.
36, no. 4, pp. 312–323, 2009.
[67] S. Romeo and A. P. Dei Tos, “Soft tissue tumors associated
with EWSR1 translocation,” Virchows Archiv, vol. 456, no. 2,
pp. 219–234, 2009.
[68] J. L. Ord´ o˜ nez, D. Osuna, D. J. Garc´ ıa-Dom´ ınguez et al.,
“The clinical relevance of molecular genetics in soft tissue
sarcomas,” Advances in Anatomic Pathology, vol. 17, no. 3, pp.
162–181, 2010.
[69] J. Zucman, T. Melot, C. Desmaze et al., “Combinatorial
generation of variable fusion proteins in the Ewing family of
tumours,” The EMBO Journal, vol. 12, no. 12, pp. 4481–4487,
1993.Sarcoma 13
[70] F. G. Barr and R. B. Womer, “Molecular diagnosis of Ewing
family tumors too many fusions...?” Journal of Molecular
Diagnostics, vol. 9, no. 4, pp. 437–440, 2007.
[71] E. De Alava, A. Kawai, J. H. Healey et al., “EWS-FLI1
fusion transcript structure is an independent determinant of
prognosis in Ewing’s sarcoma,” Journal of Clinical Oncology,
vol. 16, no. 4, pp. 1248–1255, 1998.
[72] A. Zoubek, B. Dockhorn-Dworniczak, O. Delattre et al.,
“Does expression of diﬀerent EWS chimeric transcripts
deﬁne clinically distinct risk groups of Ewing tumor
patients?” Journal of Clinical Oncology,v o l .1 4 ,n o .4 ,p p .
1245–1251, 1996.
[73] E. De Alava, A. Kawai, J. H. Healey et al., “EWS-FLI1
fusion transcript structure is an independent determinant of
prognosis in Ewing’s sarcoma,” Journal of Clinical Oncology,
vol. 16, no. 4, pp. 1248–1255, 1998.
[74] R. Codrington, R. Pannell, A. Forster et al., “The Ews-ERG
fusion protein can initiate neoplasia from lineage-committed
haematopoietic cells,” PLoS Biology, vol. 3, no. 8, article e242,
2005.
[75] L.Wang,R.Bhargava,T.Zhengetal.,“Undiﬀerentiatedsmall
roudcellsarcomaswithrareEWSgenefusions:identiﬁcation
of a novel EWS-SP3 fusion and of additional cases with
the EWS-ETV1 and EWS-FEV fusions,” Journal of Molecular
Diagnostics, vol. 9, no. 4, pp. 498–509, 2007.
[76] J. Ordi, E. De Alava, A. Torn´ e et al., “Intraabdominal
desmoplastic small round cell tumor with EWS/ERG fusion
transcript,” American Journal of Surgical Pathology, vol. 22,
no. 8, pp. 1026–1032, 1998.
[77] D.C.Shing,D.J.McMullan,P.Robertsetal.,“FUS/ERGgene
fusions in Ewing’s tumors,” Cancer Research, vol. 63, no. 15,
pp. 4568–4576, 2003.
[78] T. L. Ng, M. J. O’Sullivan, C. J. Pallen et al., “Ewing sarcoma
with novel translocation t(2;16) producing an in-ﬂame
fusion of FUS and FEV,” Journal of Molecular Diagnostics, vol.
9, no. 4, pp. 459–463, 2007.
[79] G. Armengol, M. Tarkkanen, M. Virolainen et al., “Recurrent
gains of 1q, 8 and 12 in the Ewing family of tumours
by comparative genomic hybridization,” British Journal of
Cancer, vol. 75, no. 10, pp. 1403–1409, 1997.
[80] M. Tarkkanen, S. Kiuru-Kuhlefelt, C. Blomqvist et al., “Clin-
ical correlations of genetic changes by comparative genomic
hybridization in Ewing sarcoma and related tumors,” Cancer
Genetics and Cytogenetics, vol. 114, no. 1, pp. 35–41, 1999.
[81] M. R. Nucci, S. Weremowicz, D. M. Neskey et al., “Genetic
imbalances revealed by comparative genomic hybridization
in Ewing tumors,” Genes Chromosomes and Cancer, vol. 32,
no. 2, pp. 164–171, 2001.
[82] S. Savola, A. Klami, A. Tripathi et al., “Combined use of
expression and CGH arrays pinpoints novel candidate genes
in Ewing sarcoma family of tumors,” BMC Cancer, vol. 9,
article 17, 2009.
[83] A. Ohali, S. Avigad, R. Zaizov et al., “Prediction of high risk
Ewing’ssarcomabygeneexpressionproﬁling,”Oncogene,vol.
23, no. 55, pp. 8997–9006, 2004.
[84] K.-L. Schaefer, M. Eisenacher, Y. Braun et al., “Microarray
analysisofEwing’ssarcomafamilyoftumoursrevealscharac-
teristic gene expression signatures associated with metastasis
and resistance to chemotherapy,” European Journal of Cancer,
vol. 44, no. 5, pp. 699–709, 2008.
[85] R. Smith, L. A. Owen, D. J. Trem et al., “Expression proﬁling
of EWS/FLI identiﬁes NKX2.2 as a critical target gene in
Ewing’s sarcoma,” Cancer Cell, vol. 9, no. 5, pp. 405–416,
2006.
[86] L. A. Owen and S. L. Lessnick, “Identiﬁcation of target genes
in their native cellular context: an analysis of EWS/FLI in
Ewing’s sarcoma,” Cell Cycle, vol. 5, no. 18, pp. 2049–2053,
2006.
[87] J. D. Hancock and S. L. Lessnick, “A transcriptional proﬁling
meta-analysis reveals a core EWS-FLI gene expression signa-
ture,” Cell Cycle, vol. 7, no. 2, pp. 250–256, 2008.
[ 8 8 ]S .L .L e s s n i c k ,A .P .D e iT o s ,P .H .B .S o r e n s e ne ta l . ,“ S m a l l
Round Cell Sarcomas,” Seminars in Oncology, vol. 36, no. 4,
pp. 338–346, 2009.
[89] A. Abudu, D. C. Mangham, G. M. Reynolds et al., “Over-
expression of p53 protein in primary Ewing’s sarcoma of
bone: relationship to tumour stage, response and prognosis,”
British Journal of Cancer, vol. 79, no. 7-8, pp. 1185–1189,
1999.
[90] E. De Alava, C. R. Antonescu, A. Panizo et al., “Prognostic
impact of P53 status in Ewing sarcoma,” Cancer, vol. 89, no.
4, pp. 783–792, 2000.
[91] H.-Y. Huang, P. B. Illei, Z. Zhao et al., “Ewing sarcomas with
p53 mutation or p16/p14ARF homozygous deletion: a highly
lethalsubsetassociatedwithpoorchemoresponse,”Journalof
Clinical Oncology, vol. 23, no. 3, pp. 548–558, 2005.
[92] S. C. Brownhill, C. Taylor, and S. A. Burchill, “Chromosome
9p21 gene copy number and prognostic signiﬁcance of p16
in ESFT,” British Journal of Cancer, vol. 96, no. 12, pp. 1914–
1923, 2007.
[93] J.A. Lopez-Guerrero, I. Machado, K. Scotlandi et al., “Clin-
icopathological signiﬁcance of cell cycle regulation markers
in a large series of genetically conﬁrmed Ewing’s Sarcoma
Family of Tumors,” International Journal of Cancer. In press.
[94] I. Alldinger, K. L. Schaefer, D. Goedde et al., “Microsatellite
instability in Ewing tumor is not associated with loss
of mismatch repair protein expression,” Journal of Cancer
Research and Clinical Oncology, vol. 133, no. 10, pp. 749–759,
2007.
[95] K. Gangwal, S. Sankar, P. C. Hollenhorst et al., “Microsatel-
lites as EWS/FLI response elements in Ewing’s sarcoma,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 29, pp. 10149–10154, 2008.
[96] K. Gangwal and S. L. Lessnicke, “Microsatellites are EWS/FLI
response elements: genomic “junk“ is EWS/FLI’s treasure,”
Cell Cycle, vol. 7, no. 20, pp. 3127–3132, 2008.
[97] M. Kinsey, R. Smith, and S. L. Lessnick, “NR0B1 is required
for the oncogenic phenotype mediated by EWS/FLI in
Ewing’s sarcoma,” Molecular Cancer Research, vol. 4, no. 11,
pp. 851–859, 2006.
[98] N. Riggi, M.-L. Suv` a, D. Suv` a et al., “EWS-FLI-1 expression
triggers a Ewing’s sarcoma initiation program in primary
humanmesenchymalstemcells,”CancerResearch,vol.68,no.
7, pp. 2176–2185, 2008.
[99] E. C. Torchia, S. Jaishankar, and S. J. Baker, “Ewing tumor
fusion proteins block the diﬀerentiation of pluripotent
marrow stromal cells,” Cancer Research, vol. 63, no. 13, pp.
3464–3468, 2003.
[100] N. Riggi, M.-L. Suv` a, C. De Vito et al., “EWS-FLI-1
modulates miRNA145 and SOX2 expression to initiate mes-
enchymal stem cell reprogramming toward Ewing sarcoma
cancer stem cells,” Genes and Development,v o l .2 4 ,n o .9 ,p p .
916–932, 2010.
[101] S.Hu-Lieskovan,J.Zhang,L.Wuetal.,“EWS-FLI1fusinpro-
tein up-regulates critical genes in neurtal crest development
and is responsible for the observed phenotype of Ewing’s
family of tumors,” Cancer Research, vol. 65, no. 11, pp. 4633–
4644, 2005.14 Sarcoma
[102] F. Baliko, T. Bright, R. Poon, B. Cohen, S. E. Egan, and
B. A. Alman, “Inhibition of notch signaling induces neural
diﬀerentiation in Ewing sarcoma,” American Journal of
Pathology, vol. 170, no. 5, pp. 1686–1694, 2007.
[103] R. L. Shanfeld, J. Edelman, J. E. Willis, L. Tuason, and
J. R. Goldblum, “Immunohistochemical analysis of neural
markers in peripheral primitive neuroectodermal tumors
(pPNET) without light microscopic evidence of neural dif-
ferentiation,” Applied Immunohistochemistry and Molecular
Morphology, vol. 5, no. 2, pp. 78–86, 1997.
[104] D. M. Gascoyne, J. Dunne, S. Behjati, N. J. Sebire, J.
Anderson, and D. S. Latchman, “EWS/ETS proteins promote
expression and regulate function of the homeodomain
transcription factor BRN3A,” Oncogene, vol. 29, no. 21, pp.
3134–3145, 2010.
[105] J. A. van Doorninck, L. Ji, B. Schaub et al., “Current treat-
ment protocols have eliminated the prognostic advantage of
type 1 fusions in Ewing sarcoma: a report from the children’s
Oncology Group,” Journal of Clinical Oncology, vol. 28, no.
12, pp. 1989–1994, 2010.
[106] H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition
of ifosfamide and etoposide to standard chemotherapy for
Ewing’s sarcoma and primitive neuroectodermal tumor of
bone,” The New England Journal of Medicine, vol. 348, no. 8,
pp. 694–701, 2003.
[107] A. W. Craft, S. J. Cotterill, J. A. Bullimore, and D. Pearson,
“Long-term results from the ﬁrst UKCCSG Ewing’s tumour
study (ET-1),” European Journal of Cancer Part A, vol. 33, no.
7, pp. 1061–1069, 1997.
[108] S. J. Cotterill, S. Ahrens, M. Paulussen et al., “Prognostic
factors in Ewing’s tumor of bone: analysis of 975 patients
from the European Intergroup Cooperative Ewing’s Sarcoma
Study Group,” Journal of Clinical Oncology, vol. 18, no. 17,
pp. 3108–3114, 2000.
[109] N. Tageja, “Prognostic indicators for ewing’s sarcoma,” The
Lancet, vol. 376, no. 9737, p. 232, 2010.
[110] P. J. Leavey, L. Mascarenhas, N. Marina et al., “Prognostic
factors for patients with Ewing sarcoma (EWS) at ﬁrst
recurrence following multi-modality therapy: a report from
the children’s oncology group,” Pediatric Blood and Cancer,
vol. 51, no. 3, pp. 334–338, 2008.
[111] R. Ladenstein, U. P¨ otschger, M. C. Le Deley et al., “Primary
disseminated multifocal Ewing sarcoma: results of the Euro-
EWING 99 trial,” Journal of Clinical Oncology, vol. 28, no. 20,
pp. 3284–3291, 2010.
[112] M. Paulussen, S. Ahrens, S. Burdach et al., “Primary
metastatic (stage IV) Ewing tumor: survival analysis of 171
patients from the EICESS studies,” Annals of Oncology, vol. 9,
no. 3, pp. 275–281, 1998.
[113] M. Paulussen, S. Ahrens, A. W. Craft et al., “Ewing tumors
with primary lungmetastases: survival analysis of 114 (Euro-
peanIntergroup)EwingSarcomaStudiespatients,”Journalof
Clinical Oncology, vol. 16, pp. 3044–3052, 1998.
[114] C. Rodr´ ıguez-Galindo, T. Liu, M. J. Krasin et al., “Analysis
of prognostic factors in Ewing sarcoma family of tumors,”
Cancer, vol. 110, no. 2, pp. 375–384, 2007.
[115] H. Jurgens, U. Exner, H. Gardner et al., “Multidisciplinary
treatment of primary Ewing’s sarcoma of bone,” Cancer, vol.
7, pp. 208–213, 1988.
[116] J. S. Miser, M. D. Kraito, and N. J. Tarbell, “Treatment of
metastatic Ewing’s sarcoma or primitive neuroectodermal
tumor of bone: evaluation of combination ifosfamide and
etoposide: a children’s Cancer group and Pediatric Oncology
Group study,” Journal of Clinical Oncology, vol. 22, pp. 2873–
2876, 2004.
[117] C. Rodr´ ıguez-Galindo, F. Navid, T. Liu, C. A. Billups, B.
N. Rao, and M. J. Krasin, “Prognostic factors for local and
distant control in Ewing sarcoma family of tumors,” Annals
of Oncology, vol. 19, no. 4, pp. 814–820, 2008.
[118] C. Rodriguez-Galindo, S. L. Spunt, and A. S. Pappo, “Review
treatment of ewing sarcoma family of tumors: current status
and outlook for the future,” Medical Pediatric Oncology, vol.
40, pp. 276–287, 2003.
[119] M. Paulussen, S. Ahrens, J. Dunst et al., “Localized Ewing
tumor of bone: ﬁnal results of the cooperative Ewing’s
Sarcoma study CESS 86,” Journal of Clinical Oncology, vol.
19, no. 6, pp. 1818–1829, 2001.
[120] R. Derek Jenkin, I. Al-Fawaz, M. Al-Shabanah et al.,
“Localised Ewing sarcoma/PNET of bone—prognostic fac-
tors and international data comparison,” Medical and Pedi-
atric Oncology, vol. 39, no. 6, pp. 586–593, 2002.
[121] G. Bacci, S. Ferrari, A. Longhi et al., “Prognostic signiﬁcance
of serum LDH in Ewing’s sarcoma of bone,” Oncology
Reports, vol. 6, no. 4, pp. 807–811, 1999.
[122] C. M. Hattinger, U. Potsguer, M. Tarkannen et al., “Prognos-
tic impact of chromosomal aberrations in Ewing tumors,”
British Journal of Cancer, vol. 86, pp. 1763–1769, 2002.
[123] G. Wei, C. R. Antonescu, E. De Alava et al., “Prognostic
impact of INK4A deletion in Ewing sarcoma,” Cancer, vol.
89, no. 4, pp. 793–799, 2000.
[124] A. A. Gupta, A. Pappo, and N. Saunders, “Clinical outcome
of children and adults with localized Ewing sarcoma, impact
of chemotherapy dose and timing of local therapy,” Cancer,
vol. 116, pp. 3189–3194, 2010.
[125] S. Ferrari, F. Bertoni, E. Palmerini et al., “Predictive fac-
tors of histologic response to primary chemotherapy in
patients with ewing sarcoma,” Journal of Pediatric Hematol-
ogy/Oncology, vol. 29, no. 6, pp. 364–368, 2007.
[126] G. Bacci, S. Ferrari, F. Bertoni et al., “Prognostic factors
in nonmetastatic Ewing’s sarcoma of bone treated with
adjuvant chemotherapy: analysis of 359 patients at the
IstitutoOrtopedicoRizzoli,” JournalofClinicalOncology, vol.
18, no. 1, pp. 4–11, 2000.
[127] M. W. Verrill, I. R. Judson, C. L. Harmer, C. Fisher, J. M.
Thomas, and E. Wiltshaw, “Ewing’s sarcoma and primitive
neuroectodermal tumor in adults: are they diﬀerent from
Ewing’s sarcoma and primitive neuroectodermal tumor in
children?” Journal of Clinical Oncology,v o l .1 5 ,n o .7 ,p p .
2611–2621, 1997.
[128] K. Fizazi, N. Dohollou, J.-Y. Blay et al., “Ewing’s family
of tumors in adults: multivariate analysis of survival and
long-term results of multimodality therapy in 182 patients,”
Journal of Clinical Oncology, vol. 16, no. 12, pp. 3736–3743,
1998.
[129] J. Lee, B. H. Hoang, A. Ziogas, and J. A. Zell, “Analysis of
prognostic factors in Ewing sarcoma using a population-
based cancer registry,” Cancer, vol. 116, no. 8, pp. 1964–1973,
2010.
[130] F. A. Hayes, E. I. Thompson, W. H. Meyer et al., “Therapy
for localized Ewing’s sarcoma of bone,” Journal of Clinical
Oncology, vol. 7, no. 2, pp. 208–213, 1989.
[131] N.M.Marina,A.S.Pappo,D.M.Parhametal.,“Chemother-
apy dose-intensiﬁcation for pediatric patients with Ewing’s
family of tumors and desmoplastic small round-cell tumors:
a feasibility study at St. Jude children’s research hospital,”
JournalofClinicalOncology,vol.17,no.1,pp.180–190,1999.Sarcoma 15
[132] M. Paulussen, A. W. Craft, I. Lewis et al., “Results of the
EICESS-92 study: two randomized trials of Ewing’s sarcoma
treatment—cyclophosphamide compared with ifosfamide in
standard-risk patients and assessment of beneﬁt of etoposide
added to standard treatment in high-risk patients,” Journal of
Clinical Oncology, vol. 26, no. 27, pp. 4385–4393, 2008.
[133] S. G. DuBois and H. E. Grier, “Chemotherapy: the role of
ifosfamide and etoposide in Ewing sarcoma,” Nature Reviews
Clinical Oncology, vol. 6, no. 5, pp. 251–253, 2009.
[134] R. Evans, M. Nesbit, and F. Askin, “Local recurrence, rate
and sites of metastases, and time to relapse as a function of
treatment regimen, size of primary and surgical history in 62
patients presenting with non-metastatic Ewing’s sarcoma of
thepelvicbones,”InternationalJournalofRadiationOncology
Biology Physics, vol. 11, no. 1, pp. 129–136, 1985.
[135] E. O. Burgert Jr., M. E. Nesbit, L. A. Garnsey et al.,
“Multimodal therapy for the management of nonpelvic,
localized Ewing’s sarcoma of bone: intergroup study IESS-
II,” Journal of Clinical Oncology, vol. 8, no. 9, pp. 1514–1524,
1990.
[136] A. Craft, S. Cotterill, A. Malcolm et al., “Ifosfamide-
containing chemotherapy in Ewing’s sarcoma: the second
United Kingdom children’s Cancer Study Group and the
Medical Research Council Ewing’s Tumor Study,” Journal of
Clinical Oncology, vol. 16, no. 11, pp. 3628–3633, 1998.
[137] H. Grier, M. Krailo, and M. Link, “Improved outcome in
non metastatic Ewing’s Sarcoma (ES) and PPNET of bone
with the addition of ifosfamide (I) and etoposide (E) to
vincristine (V), adryamicin (Ad), cyclophosphamide (C),
and actinomycin (A) : A Children’s Cancer group (CCG)
and Pediatrin Oncology Group (POG) report,” Procceedings
Annual Meeting American Society Clinical Oncology, vol. 13,
1994, abstract no. 421.
[138] R.Luksch,G.Sampietro,P.Collinietal.,“Prognosticvalueof
clinicopathologic characteristics including neuroectodermal
diﬀerentiation in osseous Ewing’s sarcoma family of tumors
in children,” Tumori, vol. 85, no. 2, pp. 101–107, 1999.
[139] L. Granowetter, R. Womer, M. Devidas et al., “Dose-
intensiﬁed compared with standard chemotherapy for non-
metastatic ewing sarcoma family of tumors: a children’s
oncology group study,” Journal of Clinical Oncology, vol. 27,
no. 15, pp. 2536–2541, 2009.
[140] P. S. Dickman, F. B. Askin, J. Miser et al., “Pathology and
prognosis in osseous Ewing’s sarcoma-primitive neuroecto-
dermal tumor (ES/PNET): preliminary data analysis from
CCG 7881/POG 8850,” Modern Pathology, vol. 12, p. 2, 1999.
[141] G. Bacci, C. Forni, A. Longhi et al., “Long-term outcome
for patients with non-metastatic Ewing’s sarcoma treated
withadjuvantandneoadjuvant chemotherapies.402patients
treated at Rizzoli between 1972 and 1992,” European Journal
of Cancer, vol. 40, no. 1, pp. 73–83, 2004.
[142] G. Bacci, A. Longhi, S. Ferrari, M. Mercuri, M. Versari,
and F. Bertoni, “Prognostic factors in non-metastatic Ewing’s
sarcoma tumor of bone: an analysis of 579 patients treated at
asingleinstitutionwithadjuvantorneoadjuvantchemother-
apy between 1972 and 1998,” Acta Oncologica, vol. 45, no. 4,
pp. 469–475, 2006.
[143] P. Marec-B´ erard, F. Chotel, and L. Claude, “Tumeurs
PNET/Ewing: prise en charge actuelle et perspectives,”
Bulletin du Cancer, vol. 97, no. 6, pp. 707–713, 2010.
[144] N. J. Balamuth and R. B. Womer, “Ewing’s sarcoma,” The
Lancet Oncology, vol. 11, no. 2, pp. 184–192, 2010.
[145] C.-S. Chen, J. T. Lin, K. A. Goss, Y.-A. He, J. R. Halpert,
and D. J. Waxman, “Activation of the anticancer pro-
drugs cyclophosphamide and ifosfamide: identiﬁcation of
cytochrome P450 2B enzymes and site-speciﬁc mutants with
improved enzyme kinetics,” Molecular Pharmacology, vol. 65,
no. 5, pp. 1278–1285, 2004.
[146] C.D.Scripture,A.Sparreboom,andW.D.Figg,“Modulation
of cytochrome P450 activity: implications for cancer ther-
apy,” The Lancet Oncology, vol. 6, no. 10, pp. 780–789, 2005.
[147] K.-I. Fujita, “Cytochrome P450 and anticancer drugs,”
Current Drug Metabolism, vol. 7, no. 1, pp. 23–37, 2006.
[148] M. Furlanut and L. Franceschi, “Phramacology of Ifos-
famide,” Oncology, vol. 65, supplement 2, pp. 2–6, 2003.
[149] K.Scotlandi,D.Remondini,G.Castellanietal.,“Overcoming
resistance to conventional drugs in Ewing sarcoma and
identiﬁcation of molecular predictors of outcome,” Journal
of Clinical Oncology, vol. 27, no. 13, pp. 2209–2216, 2009.
[150] D. M. Townsend and K.D. Tew, “The role of gluthatione-S-
transferasse in anticancer drug resistance,” Oncogene, vol. 22,
pp. 7369–7375, 2003.
[151] M. Salzer-Kuntschik, G. Delling, G. Beron et al., “Mor-
phologicla grades of regression in osteosarcoma after poly-
chemotherapy COSS 80,” Journal of Cancer Research Clinical
Oncology, vol. 106, supplement 1, pp. 21–24, 1983.
[152] R. B. Womer, D. C. West, M. D. Krailo et al., “Ran-
domized comparison of every-two-week v. every-three-week
chemotherapy in Ewing sarcoma family of tumors (ESFT),”
Journal of Clinical Oncology, vol. 26, supplement 15, 2008,
abstract no. 10504.
[153] U. Dirksen and H. J¨ urgens, “Approaching Ewing sarcoma,”
Future Oncology, vol. 6, no. 7, pp. 1155–1162, 2010.
[154] G. Ricci, F. De Maria, G. Antonini et al., “-7,nitro-2,1,3 ben-
zoxadiazole derivatives a new class 0f suicide inhibitors for
gluthatione S-transferases . Mechanism of action of potential
anticancer drugs,” The Journal of Biological Chemistry, vol.
280, pp. 26397–26405, 2005.
[155] E. C. Toomey, J. D. Schiﬀman, and S. L. Lessnick, “Recent
advances in the molecular pathogenesis of Ewing’s sarcoma,”
Oncogene, vol. 29, no. 32, pp. 4504–4516, 2010.
[156] G. Maire, C. W. Brown, J. Bayani et al., “Complex rearrange-
ment of chromosomes 19, 21, and 22 in Ewing sarcoma
involving a novel reciprocal inversion-insertion mechanism
of EWS-ERG fusion gene formation: a case analysis and
literature review,” Cancer Genetics and Cytogenetics, vol. 181,
no. 2, pp. 81–92, 2008.